Drug class
Antifibrinolytic agent; synthetic lysine analogue
Mechanism of action
Competitively inhibits plasminogen activation and, at higher concentrations, inhibits plasmin activity by blocking lysine-binding sites required for interaction with fibrin. This stabilises formed fibrin clots and reduces excessive fibrinolysis.
General use cases
- Treatment of acute bleeding due to elevated fibrinolytic activity, including selected bleeding associated with cardiac surgery, haematological disorders and other settings where hyperfibrinolysis is documented; use requires clinical assessment of the cause of bleeding
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
